ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för evofosfamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

37 träffar

Bibliografisk träff 2024-07-09

Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug.

Kishimoto S, Crooks DR, Yasunori O, Kota Y, Yamamoto K, Linehan WM, Levine M, Krishna MC, Brender JR.

Free Radic Biol Med · journal article · DOI 10.1016/j.freeradbiomed.2024.07.008

Bibliografisk träff 2024-05-08

[<sup>18</sup>F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response.

McNeal KC, Reeves KM, Song PN, Lapi SE, Sorace AG, Larimer BM.

Nucl Med Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.nucmedbio.2024.108918

Bibliografisk träff 2024-05-01

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Clin Cancer Res · published erratum · DOI 10.1158/1078-0432.ccr-24-1058

Bibliografisk träff 2024-02-11

Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.

Wang B, Qi FZ, Chen P, Qian LM, Su HS, Wang Y, Wang CH, Hou YX, Zhang Q, Li D, Chen ZS, Zhang SH.

Int J Biol Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/ijbs.92211

Bibliografisk träff 2024-01-09

Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.

Liu A, Gammon ST, Pisaneschi F, Boda A, Ager CR, Piwnica-Worms D, Hong DS, Curran MA.

JCI Insight · research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.169150

Bibliografisk träff 2023-12-01

<i>In Vitro</i> Characterization of the Bacteria-derived Hypoxia-selective Cytotoxin BE-43547.

Busk M, Eggertsen PP, Overgaard J, Horsman MR, Tørring T, Jacobsen KM, Poulsen TB.

Anticancer Res · journal article · DOI 10.21873/anticanres.16735

Bibliografisk träff 2023-11-22

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.

Wang Z, Zhu M, Dong R, Cao D, Li Y, Chen Z, Cai J, Zuo X.

J Nanobiotechnology · research-article; journal article · DOI 10.1186/s12951-023-02203-8

Bibliografisk träff 2023-11-22

Influence of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) on Glycolytic Metabolism of Canine Glioma: A Potential Improvement in Cancer Metabolism.

Yamazaki H, Onoyama S, Gotani S, Deguchi T, Tamura M, Ohta H, Iwano H, Nishida H, Dickinson PJ, Akiyoshi H.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15235537

Bibliografisk träff 2023-09-01

Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.

Lima EABF, Song PN, Reeves K, Larimer B, Sorace AG, Yankeelov TE.

Math Biosci Eng · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3934/mbe.2023783

Bibliografisk träff 2023-05-23

Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.

Otowa Y, Kishimoto S, Saida Y, Yamashita K, Yamamoto K, Chandramouli GVR, Devasahayam N, Mitchell JB, Krishna MC, Brender JR.

Antioxid Redox Signal · research support, n.i.h., intramural; research-article; journal article · DOI 10.1089/ars.2022.0118

Bibliografisk träff 2022-09-26

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide.

Lodi A, Pandey R, Chiou J, Bhattacharya A, Huang S, Pan X, Burgman B, Yi SS, Tiziani S, Brenner AJ.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2022.900082

Bibliografisk träff 2021-07-14

Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.

Grande E, Rodriguez-Antona C, López C, Alonso-Gordoa T, Benavent M, Capdevila J, Teulé A, Custodio A, Sevilla I, Hernando J, Gajate P, Molina-Cerrillo J, Díez JJ, Santos M, Lanillos J, García-Carbonero R.

Oncologist · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/onco.13885

Bibliografisk träff 2021-05-19

Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.

Ding Y, Yang R, Yu W, Hu C, Zhang Z, Liu D, An Y, Wang X, He C, Liu P, Tang Q, Chen D.

J Nanobiotechnology · research-article; journal article · DOI 10.1186/s12951-021-00891-8

Bibliografisk träff 2021-04-19

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy.

Li Y, Zhao L, Li XF.

Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2021.636892

Bibliografisk träff 2021-04-09

Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations.

Bailleul Q, Navarin P, Arcicasa M, Bal-Mahieu C, Carcaboso AM, Le Bourhis X, Furlan A, Meignan S, Leblond P.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13081804

Bibliografisk träff 2021-03-11

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.

Jardim-Perassi BV, Mu W, Huang S, Tomaszewski MR, Poleszczuk J, Abdalah MA, Budzevich MM, Dominguez-Viqueira W, Reed DR, Bui MM, Johnson JO, Martinez GV, Gillies RJ.

Theranostics · research-article; journal article; research support, n.i.h., extramural · DOI 10.7150/thno.56595

Bibliografisk träff 2021-01-27

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.

Brenner AJ, Floyd J, Fichtel L, Michalek J, Kanakia KP, Huang S, Reardon D, Wen PY, Lee EQ.

Sci Rep · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-021-81841-0

Bibliografisk träff 2021-01-08

Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.

Xu Y, Guo J, Liu J, Xie Y, Li X, Jiang H, Wang J, Peng Z, Wang J, Wang S, Wan C, Chen L, Zhong Y, Liu B, Liu Z.

Oncogene · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41388-020-01590-8

Bibliografisk träff 2020-12-01

Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere.

Ma P, Chen J, Qu H, Li Y, Li X, Tang X, Song Z, Xin H, Zhang J, Nai J, Li Z, Wang Z.

Drug Deliv · research-article; journal article · DOI 10.1080/10717544.2020.1831102

Bibliografisk träff 2020-09-15

Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.

Kishimoto S, Brender JR, Chandramouli GVR, Saida Y, Yamamoto K, Mitchell JB, Krishna MC.

Antioxid Redox Signal · research support, n.i.h., intramural; research-article; journal article · DOI 10.1089/ars.2020.8131

Bibliografisk träff 2019-08-17

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.

Spiegelberg L, van Hoof SJ, Biemans R, Lieuwes NG, Marcus D, Niemans R, Theys J, Yaromina A, Lambin P, Verhaegen F, Dubois LJ.

Radiother Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.radonc.2019.06.034

Bibliografisk träff 2019-07-13

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.

Harms JK, Lee TW, Wang T, Lai A, Kee D, Chaplin JM, McIvor NP, Hunter FW, Macann AMJ, Wilson WR, Jamieson SMF.

Cells · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/cells8070717

Bibliografisk träff 2019-04-12

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR.

Mol Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1124/mol.118.115196

Bibliografisk träff 2018-12-31

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.

Hong CR, Wilson WR, Hicks KO.

Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.neo.2018.11.009

Bibliografisk träff 2018-08-19

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2018.08.027

Bibliografisk träff 2018-05-31

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.

Kumar S, Sun JD, Zhang L, Mokhtari RB, Wu B, Meng F, Liu Q, Bhupathi D, Wang Y, Yeger H, Hart C, Baruchel S.

Transl Oncol · research-article; journal article · DOI 10.1016/j.tranon.2018.05.004

Bibliografisk träff 2018-05-03

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.

Huang Y, Tian Y, Zhao Y, Xue C, Zhan J, Liu L, He X, Zhang L.

Cancer Commun (Lond) · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s40880-018-0285-0

Bibliografisk träff 2017-09-08

Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.

Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart CP, Mitchell JB, Krishna MC.

Antioxid Redox Signal · research-article; journal article · DOI 10.1089/ars.2017.7106

Bibliografisk träff 2017-07-31

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.

Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL.

Transl Oncol · research-article; journal article · DOI 10.1016/j.tranon.2017.06.010

Bibliografisk träff 2017-02-25

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI.

Cancer Chemother Pharmacol · clinical trial, phase i; journal article · DOI 10.1007/s00280-017-3256-2